statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tharimmune, Inc. (NASDAQ:THAR  Get Free Report) saw a large decrease in short interest in March. As of March 15th, there was short interest totalling 22,800 shares, a decrease of 69.9% from...

Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Decreases By 69.9%

MIAMI, March 06, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 68th Emerging Growth Conference on March 6 & 7, 2024. The...

Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now

MIAMI, March 05, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 68th Emerging Growth Conference on March 6 & 7, 2024. The...

Presenting on the Emerging Growth Conference 68 Day 1 on March 6 Register Now

Tharimmune invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth ConferenceBRIDGEWATER, NJ...

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Positive safety/tolerability profile achieved with TH104 showing self-resolving, mild side effect profile aligned with previous studiesPhase 1 clinical trial compared oral transmucosal delivery of...

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Tharimmune doses first patient in Phase 1 trial of TH104

Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavailability of TH104Phase 1 study expected to be completed in 1Q24 with...

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Tharimmune provides update on TH-3215, TH-1940 non clinical-stage programs

Tharimmune provides update on TH104 clinical-stage program

Tharimmune initiates Phase 1 trial of TH104

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or uncontrollable itching in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.

Watchers	2,069
52-Wk Low	$0.3439
52-Wk High	$10.87

Volume	82,694.00
52-Wk High	$10.87
52-Wk Low	$0.3439

Period	Estimated	Reported	Surprise	Result
Q4'23	-$1.00	--	--	N/A
Q3'23	-$1.25	--	--	N/A
Q2'23	-$4.00	--	--	N/A
Q1'23	-$5.75	--	--	N/A

THAR Hillstream BioPharma Inc

About

Feed

News

Earnings

Fundamentals